/PHAR
PHAR Stock - Pharming Group N.V.
Healthcare|BiotechnologyNASDAQ
$16.62+1.96%
+$0.32 (+1.96%) • Dec 19
88
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.93
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+152.7%upside
Target: $42.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for PHAR
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$16.45 – $16.79
TARGET (TP)$42.00
STOP LOSS$15.29
RISK/REWARD1:19.1
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.18
52W High$18.12
52W Low$7.50
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $297.20M | $245.32M | $205.62M | $198.87M | $212.17M |
| Gross Profit | $261.80M | $220.10M | $188.06M | $177.73M | $188.63M |
| Gross Margin | 88.1% | 89.7% | 91.5% | 89.4% | 88.9% |
| Operating Income | $-8,621,000 | $-5,387,000 | $18.23M | $13.56M | $76.26M |
| Net Income | $-11,841,000 | $-10,548,000 | $13.67M | $16.00M | $37.75M |
| Net Margin | -4.0% | -4.3% | 6.7% | 8.0% | 17.8% |
| EPS | $-0.17 | $-0.14 | $0.17 | $0.20 | $0.47 |
Company Overview
Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
1 Bullish0 Neutral/Bearish
Price Targets
$14
Average Target
↓ 15.8% Downside
Now
$14
Low
$14
Average
$14
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 9th 2024 | Jefferies | Initiation | Buy | $14 |
Earnings History & Surprises
PHARBeat Rate
38%
Last 16 quarters
Avg Surprise
-352.7%
EPS vs Estimate
Beats / Misses
6/9
1 met exactly
Latest EPS
$0.10
Q4 2025
EPS Surprise History
Q1 24
-160.0%
$-0.03vs$0.05
Q2 24
-2000.0%
$-0.19vs$0.01
Q3 24
-400.0%
$-0.01vs$-0.00
Q4 24
-300.0%
$-0.02vs$0.01
Q1 25
-28.6%
$0.05vs$0.07
Q2 25
+12.0%
$-0.22vs$-0.25
Q3 25
+160.0%
$0.06vs$-0.10
Q4 25
+100.0%
$0.10vs$0.05
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Mar 12, 2026 | $0.18 | — | — | — |
Q4 2025 | Nov 6, 2025 | $0.05 | $0.10 | +100.0% | ✓ BEAT |
Q3 2025 | Jul 31, 2025 | $-0.10 | $0.06 | +160.0% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $-0.25 | $-0.22 | +12.0% | ✓ BEAT |
Q1 2025 | Mar 13, 2025 | $0.07 | $0.05 | -28.6% | ✗ MISS |
Q4 2024 | Oct 24, 2024 | $0.01 | $-0.02 | -300.0% | ✗ MISS |
Q3 2024 | Aug 1, 2024 | $-0.00 | $-0.01 | -400.0% | ✗ MISS |
Q2 2024 | May 8, 2024 | $0.01 | $-0.19 | -2000.0% | ✗ MISS |
Q1 2024 | Mar 14, 2024 | $0.05 | $-0.03 | -160.0% | ✗ MISS |
Q4 2023 | Oct 26, 2023 | $0.13 | $0.05 | -61.5% | ✗ MISS |
Q3 2023 | Aug 3, 2023 | $-0.02 | $0.02 | +200.0% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-0.01 | $-0.17 | -1600.0% | ✗ MISS |
Q1 2023 | Mar 16, 2023 | $0.01 | $-0.19 | -2000.0% | ✗ MISS |
Q4 2022 | Oct 27, 2022 | $0.02 | $0.01 | -48.7% | ✗ MISS |
Q3 2022 | Aug 4, 2022 | $0.01 | $0.04 | +300.0% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $-0.06 | $0.05 | +183.3% | ✓ BEAT |
Q1 2022 | Mar 17, 2022 | $0.01 | $0.01 | 0.0% | = MET |
Q3 2021 | Aug 9, 2021 | — | $-0.00 | — | — |
Q2 2021 | Apr 7, 2021 | — | $0.02 | — | — |
Latest News
Pharming Group shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY25 sales guidance above estimates.
📈 PositiveBenzinga•Nov 6, 2025, 01:52 PM•Also:
Pharming Raises FY2025 Sales Guidance from $335.000M-$350.000M to $365.000M-$375.000M vs $339.625M Est
📈 PositiveBenzinga•Nov 6, 2025, 08:19 AM
Pharming Q3 EPS $0.10 Beats $(0.00) Estimate, Sales $97.300M Beat $93.430M Estimate
📈 PositiveBenzinga•Nov 6, 2025, 06:07 AM
Pharming Group To Present 12 Abstracts At ACAAI 2025 Highlighting New Data For RUCONEST And Joenja Across Rare Diseases
📈 PositiveBenzinga•Oct 20, 2025, 06:50 AM•Also:
Pharming Group Announces Restructuring With 20% Headcount Reduction To Cut Costs By $10M Annually; Anticipates One-Time Restructuring Costs Of ~$7M To Be Recorded In Q4 2025 In Connection With The Headcount Reduction
📉 NegativeBenzinga•Oct 6, 2025, 03:41 PM•Also:
Pharming Group Gains FDA Priority Review For Leniolisib sNDA In Children With APDS Ages 4 To 11 Years
📈 PositiveBenzinga•Oct 1, 2025, 05:30 AM•Also:
Pharming Group Promoted To Euronext AMX Index From AScX Effective September 22, Reflecting Strong Growth Momentum And Visibility
📈 PositiveBenzinga•Sep 10, 2025, 06:18 AM•Also: ,
Pharming Group Appoints Kenneth Lynard As Chief Financial Officer Effective October 1, 2025
➖ NeutralBenzinga•Sep 2, 2025, 07:45 AM•Also:
Frequently Asked Questions about PHAR
What is PHAR's current stock price?
Pharming Group N.V. (PHAR) is currently trading at $16.62 per share. The stock has moved +1.96% today.
What is the analyst price target for PHAR?
The average analyst price target for PHAR is $42.00, based on 1 analyst.
What sector is Pharming Group N.V. in?
Pharming Group N.V. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is PHAR's market cap?
Pharming Group N.V. has a market capitalization of $1.14 billion, making it a small-cap company.
Does PHAR pay dividends?
No, Pharming Group N.V. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABUS
Arbutus Biopharma Corporation
$4.43
Mkt Cap: $0.9B
BCAX
Bicara Therapeutics Inc. Common Stock
$17.60
Mkt Cap: $1.0B
EYPT
EyePoint Pharmaceuticals, Inc.
$17.43
Mkt Cap: $1.2B
FTRE
Fortrea Holdings Inc.
$17.74
Mkt Cap: $1.6B
KURA
Kura Oncology, Inc.
$9.84
Mkt Cap: $0.9B
MNMD
Mind Medicine (MindMed) Inc.
$12.70
Mkt Cap: $1.0B
PROK
ProKidney Corp.
$2.37
Mkt Cap: $0.3B
PVLA
Palvella Therapeutics, Inc.
$99.73
Mkt Cap: $1.2B
SEPN
Septerna, Inc.
$29.58
Mkt Cap: $1.3B
TNGX
Tango Therapeutics, Inc.
$8.52
Mkt Cap: $0.9B
Explore stocks similar to PHAR for comparison